Smartee S22: Incorporating GS MART Technology into Occlusal Reconstructive Therapy in Prosthodontics
SHENZHEN, China, July 10, 2026 /PRNewswire/ -- Smartee Denti-Technology has announced the launch of S22: GS MART (Mandibular Repositioning Technology) for Occlusal Reconstruction in Prosthodontic Dentistry, expanding the clinical application of its GS MART into prosthodontic dentistry. The project was jointly developed by Smartee Denti-Technology and Prof. Gang Shen's orthodontic team at Taikang Dental Group. ...
Puncture Robotic Showcases AI-Powered Hair Restoration Innovation at WCHR 2026
SEOUL, South Korea, July 10, 2026 /PRNewswire/ -- Artificial intelligence is rapidly reshaping medical aesthetics, and hair restoration is undergoing a significant technological transformation. At the 14th World Congress for Hair Research (WCHR 2026), Puncture Robotic attracted international attention with the debut of its HAIRO Hair Transplant Robot and its vision for AI-powered hair transplantation. ...
Medical AI Ecosystem Innovation Forum and iMedLoop Global Medical Imaging Data Platform Launch Held in Beijing
When Healthcare Meets AI: A New Era of Ecosystem-wide Innovation Is Accelerating BEIJING, July 10, 2026 /PRNewswire/ -- On July 4, the Medical AI Ecosystem Innovation Forum and iMedLoop Global Medical Imaging Data Platform Launch was held in Beijing. Jointly organized by Liaowang Finance, under Liaowang Weekly, and Diagens Technology, the event was guided by the theme of "AI...
Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
NANJING, China, July 10, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific antibody) as monotherapy for the treatment of advanced extrapulmonary neuroendocrine carcinoma (EP-NEC) has been approved by the Center for Drug Evaluation (CDE) of the National...
POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare
GUANGZHOU, China, July 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its continued efforts in building an AI-powered chronic disease management ecosystem. The Company is integrating artificial intelligence ("AI"), remote patient monitoring ("RPM"), wearable technologies and real-world healthcare data to evolve...
POMDOCTOR LIMITED Continues to Advance AI-Enabled Chronic Disease Management Strategy Amid Growing Demand for Predictive Healthcare
GUANGZHOU, China, July 9, 2026 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare capabilities, today highlighted its continued efforts in building an AI-powered chronic disease management ecosystem. The Company is integrating artificial intelligence ("AI"), remote patient monitoring ("RPM"), wearable technologies and real-world healthcare data to evolve...
Professor Gang Shen’s Orthodontic Team Publishes Third Consecutive Paper in the Journal of Aligner Orthodontics
SHANGHAI, July 8, 2026 /PRNewswire/ -- Professor Gang Shen, Chief GS R&D Scientist of Smartee Denti-Technology and Chief Orthodontist at Taikang Dental, together with his orthodontic team, has published a new research article titled "Pathological Mandibular Retrusion: Causality and Orthodontic Intervention" in Issue 2 of 2026 of the Journal of Aligner Orthodontics (JAO). The publication marks the team's third consecutive...
InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRAS G12C Mutation
NANJING, China, July 9, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective focal adhesion kinase (FAK) inhibitor, in combination with garsorasib (D-1553), a potent KRASG12C inhibitor in first-line KRASG12C-mutant NSCLC, have been published...
WuXi Biologics’ MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License Inspection (PLI) by the U.S. Food and Drug Administration (FDA), supporting commercial manufacturing for a potential blockbuster autoimmune therapy. The seven-day FDA inspection conducted...
Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine
HANGZHOU, China, July 9, 2026 /PRNewswire/ -- On July 8, the study of Betta's ensartinib as postoperative adjuvant therapy for patients with stage IB–IIIB (T3N2M0) ALK-positive non-small cell lung cancer (NSCLC), known as the ELEVATE study, was published online in full in The New England Journal of Medicine (NEJM; Impact Factor 84.5), a world-leading medical journal. The study provides...
